Takeda Pharmaceutical Fiscal Q4 Core Earnings, Revenue Rise; Issues Fiscal 2026 Outlook

MT Newswires Live

05/13

Takeda Pharmaceutical (TAK) reported fiscal Q4 core earnings Wednesday of 89 Japanese yen ($0.56) per share, down from 49 yen a year earlier.

Three analysts polled by FactSet expected 63.09 yen.

Revenue for the quarter ended March 31 was 1.095 trillion yen, up from 1.052 trillion yen a year earlier.

Analysts surveyed by FactSet expected 1.123 trillion yen.

For fiscal 2026, the drugmaker expects core EPS of 472 yen and revenue of 4.640 trillion yen. Analysts polled by FactSet are expecting EPS of 497.59 yen and sales of 4.602 trillion yen for the year.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2635203042"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2635203042\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2635203042?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 15:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635203042","market":"hk","top_or_hot":-1,"title":"Takeda Pharmaceutical Fiscal Q4 Core Earnings, Revenue Rise; Issues Fiscal 2026 Outlook","media":"MT Newswires Live","content":"<html><body><p> Takeda Pharmaceutical (TAK) reported fiscal Q4 core earnings Wednesday of 89 Japanese yen ($0.56) per share, down from 49 yen a year earlier.</p><p>Three analysts polled by FactSet expected 63.09 yen.</p><p>Revenue for the quarter ended March 31 was 1.095 trillion yen, up from 1.052 trillion yen a year earlier.</p><p>Analysts surveyed by FactSet expected 1.123 trillion yen.</p><p>For fiscal 2026, the drugmaker expects core EPS of 472 yen and revenue of 4.640 trillion yen. Analysts polled by FactSet are expecting EPS of 497.59 yen and sales of 4.602 trillion yen for the year.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Takeda Pharmaceutical Fiscal Q4 Core Earnings, Revenue Rise; Issues Fiscal 2026 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTakeda Pharmaceutical Fiscal Q4 Core Earnings, Revenue Rise; Issues Fiscal 2026 Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-13 15:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Takeda Pharmaceutical (TAK) reported fiscal Q4 core earnings Wednesday of 89 Japanese yen ($0.56) per share, down from 49 yen a year earlier.</p><p>Three analysts polled by FactSet expected 63.09 yen.</p><p>Revenue for the quarter ended March 31 was 1.095 trillion yen, up from 1.052 trillion yen a year earlier.</p><p>Analysts surveyed by FactSet expected 1.123 trillion yen.</p><p>For fiscal 2026, the drugmaker expects core EPS of 472 yen and revenue of 4.640 trillion yen. Analysts polled by FactSet are expecting EPS of 497.59 yen and sales of 4.602 trillion yen for the year.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FXY","symbol_name":"日元ETF-CurrencyShares","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2635203042","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635203042","pubTimestamp":1778656131,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Takeda Pharmaceutical  reported fiscal Q4 core earnings Wednesday of 89 Japanese yen  per share, down from 49 yen a year earlier.Three analysts polled by FactSet expected 63.09 yen.Revenue for the quarter ended March 31 was 1.095 trillion yen, up from 1.052 trillion yen a year earlier.Analysts surveyed by FactSet expected 1.123 trillion yen.For fiscal 2026, the drugmaker expects core EPS of 472 yen and revenue of 4.640 trillion yen. Analysts polled by FactSet are expecting EPS of 497.59 yen and sales of 4.602 trillion yen for the year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FXY":"日元ETF-CurrencyShares","HEWJ":"日本ETF汇率对冲-iShares","BK4007":"制药","YCS":"日元ETF-ProShares两倍做空","YCL":"ProShares Ultra Yen","TAK":"武田制药"},"translate_title":"武田制药第四财季核心盈利、收入增长；发布2026财年展望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HEWJ":0.9,"TAK":1,"FXY":0.9,"YCL":0.9,"YCS":0.9},"content_text":"Takeda Pharmaceutical (TAK) reported fiscal Q4 core earnings Wednesday of 89 Japanese yen ($0.56) per share, down from 49 yen a year earlier.Three analysts polled by FactSet expected 63.09 yen.Revenue for the quarter ended March 31 was 1.095 trillion yen, up from 1.052 trillion yen a year earlier.Analysts surveyed by FactSet expected 1.123 trillion yen.For fiscal 2026, the drugmaker expects core EPS of 472 yen and revenue of 4.640 trillion yen. Analysts polled by FactSet are expecting EPS of 497.59 yen and sales of 4.602 trillion yen for the year.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}